Enanta Pharmaceuticals | ENTA - Pre Tax Profit


Enanta Pharmaceuticals reported $-22.71M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Anika Therapeutics USD -3.87M 32.43M Mar/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 73.5M Dec/2024
Biogen USD 557.3M 186.7M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Immunic USD -21.38M 8.2M Jun/2024
Incyte USD 389.94M 92.37M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
Merck USD 6.74B 22M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.2B 335M Sep/2025
Novavax USD -122.33M 286.92M Sep/2024
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025